Albendazole Tablets

Active Ingredients: Albendazole

Albendazole Tablets are a drug used to treat various parasite infections, like cystic hydatid disease or neurocysticercosis. It is sometimes used alongside other medications, like corticosteroids, to treat certain conditions. In the case of hydatid disease, it may be used alongside surgery.

Albendazole belongs to the drug class called benzimidazole anthelmintics. It exhibits broad-spectrum action against many varieties of worms, such as roundworms, tapeworms, and flukes of domestic animals and humans. It works by binding to the colchicine-sensitive site of tubulin and inhibiting its polymerization into microtubules. Those microtubules can then no longer promote glucose uptake in parasitic larval and adult stages and the parasites can no longer utilize glucose, which results in immobilization and death. Albendazole kills the worms, but eggs can survive a few weeks after treatment, so treatment may need to be repeated.

AdvaCare Pharma is a global supplier of Albendazole Tablets and Albendazole Oral Suspension. AdvaCare excels at the production of high-quality, yet cost-effective, treatments. This medication is manufactured in our GMP-certified facilities located in China, India, and the USA.

As a reputable Albendazole manufacturer, we are dedicated to ensuring that GMP guidelines and standards strictly apply to the manufacture of our entire range of 200+ pharmaceutical treatments in tablet dosage form.

AdvaCare Pharma is an American pharmaceutical company committed to the manufacture of high-quality, affordable pharmaceuticals for a global market. The extensive international network that we partner with includes pharmaceutical distributors, hospitals, pharmacies, and a variety of other medical institutions. Our vision is to manufacture Albendazole Tablets, and other quality-assured oral solid treatments, that get into the hands of those that need them most.

What is Albendazole used for?

It is used to treat infections caused by roundworms, hookworms, threadworms, whipworms, pinworms, flukes, and other parasites.

How are Albendazole Tablets used?

This medication is intended to be taken orally. Albendazole Tablets should be taken with food. Tablets may be crushed or chewed and taken with a glass of water.

Albendazole Tablets should be taken for the entire treatment duration, even if symptoms improve quickly. Missing doses can increase the risk of developing infections that are resistant to treatment.

What dose should be taken and for how long?

Refer to a doctor or pharmacist for further guidelines on dosage. Do not exceed what they advise. The dosages are based on medical condition, severity, response to treatment, age, and weight.

What if a dose is missed?

Take the dose as soon as possible unless it is almost time for the next dose. Do not take two doses at once.

Who can use Albendazole?

Albendazole can be administered to adults and children (≥ 1 year), but caution is advised for specific groups of patients.

Pregnant Animal studies have revealed evidence of embryotoxicity and skeletal malformations at subtherapeutic doses. Limited human data on the use of multiple-dose albendazole in the first trimester and single-dose albendazole in later pregnancy was not associated with an increased risk of major birth defects, miscarriage, or other adverse pregnancy outcomes.

Due to the lack of adequate and well-controlled studies in human pregnancy, albendazole should only be used during pregnancy if the potential benefit justifies any potential risk to the fetus.

Nursing Albendazole is excreted in human milk in small amounts. The potential for adverse effects to nursing infants is unknown. The benefits of breastfeeding, the clinical need for treatment, and any potential infant adverse effects should all be considered prior to initiating nursing or albendazole treatment.

Pediatric Albendazole can be administered to pediatric patients as young as 1 year old. For treating children under 1 year old, talk to your doctor.

In neurocysticercosis treatment, the efficacy of albendazole use in children appears to be similar to that in adults. Hydatid disease is uncommon in infants and young children.

Geriatric There are insufficient studies with adults ≥ 65 years old to determine whether they respond differently than adults < 65 years old. Limited data in 26 hydatid cyst patients suggest albendazole’s pharmacokinetic profile in older adults is similar to that seen in younger adults.

Other warnings

In patients with renal insufficiency, albendazole treatment has not been studied. Exercise caution when dosing such patients.

In patients with hepatic insufficiency, dosages may need to be reduced and hepatic health should be monitored. Mild to moderate elevations of hepatic enzymes (transaminases) have been associated with albendazole treatment. Elevated transaminases could increase the risk for hepatotoxicity and bone marrow suppression. Transaminases should be monitored before the start of a treatment cycle and every 2 weeks during. These elevations have generally resolved upon discontinuation of therapy.

Albendazole use has been associated with fatal cases of bone marrow suppression, granulocytopenia, aplastic anemia, and agranulocytosis. Blood counts should be monitored each 28-day cycle of therapy and every 2 weeks during therapy for all patients. Individuals with liver disease and hepatic echinococcosis are at increased risk for bone marrow suppression and should be monitored more frequently. Albendazole should be discontinued if clinically significant decreases in blood cell counts occur.

Individuals being treated for neurocysticercosis should receive steroid and anticonvulsant therapy to prevent neurological symptoms (e.g., seizures, increased intracranial pressure, focal signs) related to the inflammatory reaction caused by parasite death within the brain. They should also be examined for retinal lesions. If lesions are present, anti cysticercal therapy may be needed to counteract the possibility of inflammatory damage to the retinas caused by death of the parasite in the eye.

Patients at risk for neurocysticercosis should be evaluated prior to initiation of albendazole therapy for other indicated conditions, as treatment could uncover undiagnosed neurocysticercosis.

As with all pharmaceuticals, some unwanted effects can occur from the use of Albendazole Tablets.

For a comprehensive understanding of all potential side effects, consult a medical professional.

If any symptoms persist or worsen, or you notice any other symptoms, please call your doctor immediately.

Grapefruit products should be avoided during treatment.

Due to possible drug interactions, consult with your doctor about any medications you are taking before your treatment, especially dexamethasone, praziquantel, cimetidine, and theophylline, as they can affect the activity of albendazole.

Albendazole: placebo-controlled study in 870 patients with intestinal helminthiasis

This is a placebo-controlled study including 870 patients, from the age of 3 to 79 years that suffer from nematode and cestode infections. The patients were administered either albendazole or a placebo to address nematode and cestode infections.

All patients underwent a thorough physical examination and interview upon initial visit. Blood tests, including complete blood count and clinical blood chemistry, as well as routine urinalysis, were conducted before and at least 24 hours post-treatment. Stool examinations were made before treatment, as well as 7 and 21 days post-treatment, encompassing direct examination, egg count via the Kato technique, and fecal concentration. For ancylostomiasis and strongyloidiasis, fecal cultures were conducted with the Harada-Mori technique.

The conclusion of this study is that albendazole, administered as a single 400mg oral dose has a high efficacy against Ascaris lumbricoides, Necator americanus, Ancylostoma duodenale, and Trichuris trichiura. This drug did not show any significant side effects based on clinical indicators and biological assessments.